Expression of p-Btk and p-Lyn in neoplastic MCs as assessed by IHC
| No. . | Diagnosis . | KIT D816V . | Lyn . | p-LynTyr507 . | p-LynTyr396 . | Btk . | p-BtkTyr551 . |
|---|---|---|---|---|---|---|---|
| 01 | ISM | − | + | + | ± | ± | − |
| 02 | ISM | + | + | − | nt | + | − |
| 03 | ISM | + | + | + | nt | + | − |
| 04 | ISM | + | nt | nt | nt | ± | − |
| 05 | ISM | + | + | − | nt | + | − |
| 06 | ISM | + | + | + | ± | + | − |
| 07 | ISM | + | ± | ± | − | + | − |
| 08 | ISM | + | + | − | ± | ± | − |
| 09 | ISM | + | − | − | nt | + | − |
| 10 | ISM | + | + | + | nt | + | + |
| 11 | ISM | + | − | − | nt | − | − |
| 12 | ISM | − | + | + | − | − | − |
| 13 | ISM | + | + | − | nt | + | − |
| 14 | ISM | + | ± | − | − | + | − |
| 15 | ISM | + | − | − | nt | + | − |
| 18 | ISM | + | − | − | nt | + | − |
| 19 | ISM/CLL | + | + | + | − | + | − |
| 20 | ISM | + | + | − | + | + | + |
| 21 | ISM | + | nt | nt | nt | + | + |
| 22 | SSM | + | − | − | + | + | + |
| 23 | SSM | + | ± | − | + | − | − |
| 24 | SSM | + | + | + | + | ± | |
| 26 | SSM | + | + | + | + | + | + |
| 27 | ASM | − | + | + | + | + | + |
| 28 | ASM | + | + | + | + | + | + |
| 29 | ASM | + | + | + | nt | + | − |
| 34 | MCL | + | + | − | + | + | ± |
| 37 | MCL | − | + | + | + | + | + |
| 38 | MCL | + | + | + | + | + | + |
| No. . | Diagnosis . | KIT D816V . | Lyn . | p-LynTyr507 . | p-LynTyr396 . | Btk . | p-BtkTyr551 . |
|---|---|---|---|---|---|---|---|
| 01 | ISM | − | + | + | ± | ± | − |
| 02 | ISM | + | + | − | nt | + | − |
| 03 | ISM | + | + | + | nt | + | − |
| 04 | ISM | + | nt | nt | nt | ± | − |
| 05 | ISM | + | + | − | nt | + | − |
| 06 | ISM | + | + | + | ± | + | − |
| 07 | ISM | + | ± | ± | − | + | − |
| 08 | ISM | + | + | − | ± | ± | − |
| 09 | ISM | + | − | − | nt | + | − |
| 10 | ISM | + | + | + | nt | + | + |
| 11 | ISM | + | − | − | nt | − | − |
| 12 | ISM | − | + | + | − | − | − |
| 13 | ISM | + | + | − | nt | + | − |
| 14 | ISM | + | ± | − | − | + | − |
| 15 | ISM | + | − | − | nt | + | − |
| 18 | ISM | + | − | − | nt | + | − |
| 19 | ISM/CLL | + | + | + | − | + | − |
| 20 | ISM | + | + | − | + | + | + |
| 21 | ISM | + | nt | nt | nt | + | + |
| 22 | SSM | + | − | − | + | + | + |
| 23 | SSM | + | ± | − | + | − | − |
| 24 | SSM | + | + | + | + | ± | |
| 26 | SSM | + | + | + | + | + | + |
| 27 | ASM | − | + | + | + | + | + |
| 28 | ASM | + | + | + | + | + | + |
| 29 | ASM | + | + | + | nt | + | − |
| 34 | MCL | + | + | − | + | + | ± |
| 37 | MCL | − | + | + | + | + | + |
| 38 | MCL | + | + | + | + | + | + |
MC indicates mast cell; ISM, indolent SM; CLL, chronic lymphatic leukemia; SSM smoldering SM; ASM, aggressive SM; and MCL, mast cell leukemia.
IHC staining results for Lyn, p-LynTyr507, p-LynTyr396, Btk, and p-BtkTyr551 were generated on serial sections stained with Abs directed against these signaling molecules and an Ab against tryptase. Score of reactivity in IHC stains: + indicates positive; ±, weak reactivity; −, negative stain; and nt, not tested.